Chemed (CHE) | Financial Analysis & Statements
Chemed Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
639.3M
Gross Profit
225.2M
35.22%
Operating Income
103.6M
16.20%
Net Income
76.8M
12.00%
EPS (Diluted)
$5.48
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
558.8M
Shareholders Equity
979.4M
Debt to Equity
0.57
Cash Flow Metrics
Operating Cash Flow
123.9M
Free Cash Flow
117.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Chemed Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.5B | 2.4B | 2.3B | 2.1B | 2.1B |
| Cost of Goods Sold | 1.7B | 1.6B | 1.5B | 1.4B | 1.4B |
| Gross Profit | 823.2M | 854.3M | 798.8M | 765.1M | 769.8M |
| Gross Margin % | 32.5% | 35.1% | 35.3% | 35.8% | 36.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 417.2M | 424.4M | 395.1M | 358.7M | 366.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 417.2M | 424.4M | 395.1M | 358.7M | 366.7M |
| Operating Income | 341.2M | 366.9M | 342.8M | 347.2M | 344.0M |
| Operating Margin % | 13.5% | 15.1% | 15.1% | 16.3% | 16.1% |
| Non-Operating Items | |||||
| Interest Income | 8.7M | 14.6M | 6.3M | 355.0K | 377.0K |
| Interest Expense | 1.8M | 1.8M | 3.1M | 4.6M | 1.9M |
| Other Non-Operating Income | 7.6M | 19.7M | 4.4M | -13.3M | 7.8M |
| Pre-tax Income | 355.8M | 399.5M | 350.4M | 329.7M | 350.3M |
| Income Tax | 90.5M | 97.5M | 77.9M | 80.1M | 81.8M |
| Effective Tax Rate % | 25.4% | 24.4% | 22.2% | 24.3% | 23.3% |
| Net Income | 265.2M | 302.0M | 272.5M | 249.6M | 268.6M |
| Net Margin % | 10.5% | 12.4% | 12.0% | 11.7% | 12.6% |
| Key Metrics | |||||
| EBITDA | 425.3M | 464.7M | 416.6M | 397.1M | 412.2M |
| EPS (Basic) | $18.42 | $20.10 | $18.11 | $16.72 | $17.14 |
| EPS (Diluted) | $18.34 | $19.89 | $17.93 | $16.53 | $16.85 |
| Basic Shares Outstanding | 14398000 | 15024000 | 15050000 | 14929000 | 15671000 |
| Diluted Shares Outstanding | 14398000 | 15024000 | 15050000 | 14929000 | 15671000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Chemed Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 74.5M | 178.4M | 264.0M | 74.1M | 32.9M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 182.6M | 171.2M | 181.5M | 139.4M | 137.2M |
| Inventory | 7.5M | 8.2M | 12.0M | 10.3M | 10.1M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 302.6M | 394.7M | 500.8M | 272.6M | 230.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 131.2M | 127.3M | 126.4M | 135.7M | 125.0M |
| Goodwill | 1.4B | 1.4B | 1.3B | 1.3B | 1.3B |
| Intangible Assets | 82.8M | 92.2M | 90.3M | 99.7M | 108.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 149.0M | 137.5M | 114.3M | 102.2M | 106.8M |
| Total Non-Current Assets | 1.2B | 1.3B | 1.2B | 1.2B | 1.1B |
| Total Assets | 1.5B | 1.7B | 1.7B | 1.4B | 1.3B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 64.5M | 44.1M | 48.3M | 41.9M | 73.0M |
| Short-term Debt | 40.9M | 42.3M | 54.3M | 44.0M | 37.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 58.9M | 42.7M | 36.3M | 38.9M | 39.0M |
| Total Current Liabilities | 287.1M | 285.7M | 312.0M | 297.2M | 302.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 102.9M | 98.5M | 100.8M | 203.0M | 285.6M |
| Deferred Tax Liabilities | 19.3M | 25.9M | 30.3M | 38.6M | 23.2M |
| Other Non-Current Liabilities | 13.3M | 13.4M | 13.0M | 12.1M | 9.6M |
| Total Non-Current Liabilities | 271.7M | 263.9M | 248.2M | 346.1M | 417.1M |
| Total Liabilities | 558.8M | 549.6M | 560.2M | 643.3M | 719.4M |
| Equity | |||||
| Common Stock | 37.6M | 37.4M | 37.2M | 36.8M | 36.5M |
| Retained Earnings | 3.0B | 2.7B | 2.4B | 2.2B | 2.0B |
| Treasury Stock | 3.6B | 3.1B | 2.7B | 2.6B | 2.4B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 979.4M | 1.1B | 1.1B | 798.7M | 623.3M |
| Key Metrics | |||||
| Total Debt | 143.8M | 140.8M | 155.1M | 247.0M | 323.5M |
| Working Capital | 15.5M | 109.1M | 188.8M | -24.6M | -72.1M |
Balance Sheet Composition
Chemed Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 265.2M | 302.0M | 272.5M | 249.6M | 268.6M |
| Depreciation & Amortization | 64.8M | 63.0M | 60.9M | 59.2M | 59.1M |
| Stock-Based Compensation | 32.7M | 32.0M | 30.1M | 26.3M | 22.5M |
| Working Capital Changes | 24.1M | 3.9M | -39.4M | -35.9M | -20.3M |
| Operating Cash Flow | 383.1M | 393.2M | 319.5M | 300.1M | 306.2M |
| Investing Activities | |||||
| Capital Expenditures | 4.6M | 3.3M | 640.0K | 2.3M | 904.0K |
| Acquisitions | -225.0K | -97.4M | -4.0M | -3.5M | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | 3.5M | -94.4M | -3.8M | -2.1M | 918.0K |
| Financing Activities | |||||
| Share Repurchases | -431.5M | -361.4M | -67.7M | -114.5M | -576.0M |
| Dividends Paid | -31.7M | -27.1M | -23.5M | -22.0M | -22.0M |
| Debt Issuance | - | 0 | 0 | 100.0M | 0 |
| Debt Repayment | 0 | 0 | -97.5M | -321.2M | -25.3M |
| Financing Cash Flow | -459.9M | -415.7M | -182.0M | -572.9M | -441.8M |
| Free Cash Flow | 325.5M | 368.0M | 273.4M | 252.6M | 249.9M |
| Net Change in Cash | -73.4M | -116.9M | 133.7M | -274.9M | -134.7M |
Cash Flow Trend
Chemed Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
20.88
Forward P/E
14.39
Price to Book
5.36
Price to Sales
2.03
PEG Ratio
-2.12
Profitability Ratios
Profit Margin
10.48%
Operating Margin
16.62%
Return on Equity
25.28%
Return on Assets
13.40%
Financial Health
Current Ratio
1.05
Debt to Equity
14.68
Beta
0.48
Per Share Data
EPS (TTM)
$18.34
Book Value per Share
$71.44
Revenue per Share
$175.72
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CHE | 5.6B | 20.88 | 5.36 | 25.28% | 10.48% | 14.68 |
| HCA Healthcare | 106.0B | 16.86 | -38.44 | -244.82% | 8.97% | -17.57 |
| Tenet Healthcare | 16.5B | 12.17 | 3.88 | 27.02% | 6.60% | 160.79 |
| Pacs | 5.5B | 28.73 | 5.80 | 22.96% | 3.62% | 377.77 |
| Option Care Health | 4.5B | 22.35 | 3.36 | 15.20% | 3.67% | 96.00 |
| Amedisys | 3.3B | 39.30 | 2.69 | 6.67% | 3.56% | 35.34 |
Financial data is updated regularly. All figures are in the company's reporting currency.





